Oramed Pharmaceuticals Inc. (ORMP)

Market Cap	252.76M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	38.83M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,792
Open	6.53
Previous Close	6.48
Day's Range	6.31 - 6.62
52-Week Range	3.59 - 31.54
Beta	2.31
Analysts	Buy
Price Target	32.30 (+396.2%)
Earnings Date	Aug 3, 2022

About ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a w...

• Industry: Pharmaceuticals
• Founded: 2002
• CEO: Nadav Kidron
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: ORMP

Full Company Profile

Financial Performance

In 2021, ORMP's revenue was $2.70 million, a decrease of -0.26% compared to the previous year's $2.71 million. Losses were -$22.24 million, 93.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ORMP stock is "Buy." The 12-month stock price forecast is 32.3, which is an increase of 396.16% from the latest price.

Price Target

$32.3

(396.16% upside)

Analyst Consensus: Buy

Stock Forecasts